FDA
-
-
-
-
-
-
-
Bragar Eagel & Squire, P.C. Is Investigating Blink, Lovesac, and Sage and Encourages Investors to Contact the Firm
-
-
-
-
-
-
-
Sage Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Pipeline and Business Progress
-
-
-
-
-
-
-
SAGE Therapeutics (SAGE) Granted Orphan Drug Designation for SAGE-718 in EU
-
-
-
-
-
-
-
Sage Therapeutics and Biogen Announce FDA Accepts Filing of New Drug Application and Grants Priority Review of Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression
-
-
-
-
-
-
-
Sage Therapeutics Appoints Laura M. Gault, M.D., Ph.D. as Chief Medical Officer
-
-
-
-
-
-
-
SAGE Therapeutics (SAGE) and Biogen (BIIB) Report Phase 3 SKYLARK Study of Zuranolone in Postpartum Depression Met its Primary and All Key Secondary Endpoints
-
-
-
-
-
-
-
SAGE Therapeutics (SAGE) Presents Encouraging Results from the Phase 2 PARADIGM Study (Part A) of SAGE-718 in Patients with Mild Cognitive Impairment due to Parkinson’s Disease
-
240,661 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All